91 related articles for article (PubMed ID: 1373255)
1. [Clodronate in the palliative therapy of bone-metastasized prostatic carcinoma].
Vorreuther R; Klotz T; Engelking R
Urologe A; 1992 Mar; 31(2):63-6. PubMed ID: 1373255
[TBL] [Abstract][Full Text] [Related]
2. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
Heidenreich A; Hofmann R; Engelmann UH
J Urol; 2001 Jan; 165(1):136-40. PubMed ID: 11125382
[TBL] [Abstract][Full Text] [Related]
3. Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate.
Vorreuther R
Br J Urol; 1993 Nov; 72(5 Pt 2):792-5. PubMed ID: 7506626
[TBL] [Abstract][Full Text] [Related]
4. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.
Rodrigues P; Hering F; Campagnari JC
Prostate Cancer Prostatic Dis; 2004; 7(4):350-4. PubMed ID: 15534620
[TBL] [Abstract][Full Text] [Related]
5. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
Kylmälä T; Tammela TL; Lindholm TS; Seppänen J
Ann Chir Gynaecol; 1994; 83(4):316-9. PubMed ID: 7537482
[TBL] [Abstract][Full Text] [Related]
6. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
Piga A; Bracci R; Ferretti B; Sandri P; Nortilli R; Acito L; Pancotti A; Di Furia L; Carle F; Cellerino R
J Exp Clin Cancer Res; 1998 Jun; 17(2):213-7. PubMed ID: 9700583
[TBL] [Abstract][Full Text] [Related]
7. Clodronate in the management of bone metastases: a clinical study of 91 patients.
Serkies K; Jereczek-Fossa B; Badzio A; Jassem J
Neoplasma; 1999; 46(5):317-22. PubMed ID: 10665850
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
9. Disodium clodronate in the treatment of pain due to bone metastases.
Luzzani M; Vidili MG; Rissotto R; Nobile MT; Beghè F; Rosso R; Gottlieb A
Int J Clin Pharmacol Res; 1990; 10(4):243-6. PubMed ID: 2150406
[TBL] [Abstract][Full Text] [Related]
10. [Clodronate in treatment of tumor osteopathy. Evaluation in tumor patients with bone metastases or hypercalcemia].
Voigtmann R; Kirstein A
Fortschr Med; 1994 Feb; 112(4):43-6. PubMed ID: 7512066
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
[TBL] [Abstract][Full Text] [Related]
12. The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population.
Santangelo A; Testai M; Barbagallo P; Manuele S; Di Stefano A; Tomarchio M; Trizzino G; Musumeci G; Panebianco P; Maugeri D
Arch Gerontol Geriatr; 2006; 43(2):187-92. PubMed ID: 16325938
[TBL] [Abstract][Full Text] [Related]
13. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer.
Strang P; Nilsson S; Brändstedt S; Sehlin J; Borghede G; Varenhorst E; Bandman U; Borck L; Englund G; Selin L
Anticancer Res; 1997; 17(6D):4717-21. PubMed ID: 9494595
[TBL] [Abstract][Full Text] [Related]
14. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of hormone-refractive prostatic carcinoma with painful bone metastasis. Epirubicin vs. clodronate vs. epirubicin plus clodronate].
Heidenreich A
Urologe A; 1997 Nov; 36(6):568. PubMed ID: 9487597
[No Abstract] [Full Text] [Related]
17. Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
Elomaa I; Blomqvist C; Porkka L; Lamberg-Allardt C; Borgström GH
Bone; 1987; 8 Suppl 1():S53-6. PubMed ID: 2961355
[TBL] [Abstract][Full Text] [Related]
18. [Value of Clodronate in the treatment of bone metastasis].
Pouillart P; Beuzeboc P
Bull Cancer; 1991; 78(8):737-41. PubMed ID: 1834287
[TBL] [Abstract][Full Text] [Related]
19. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
[TBL] [Abstract][Full Text] [Related]
20. Clodronate for osteolytic metastases due to breast cancer.
Elomaa I; Blomqvist C; Porkka L; Holmström T; Taube T; Lamberg-Allardt C; Borgström GH
Biomed Pharmacother; 1988; 42(2):111-6. PubMed ID: 2971403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
